A clinical isolate of Pseudomonas aeruginosa recovered from the lower respiratory tract of an 81-year-old patient hospitalized in Belgium was sent to the national reference center to determine its resistance mechanism. PCR sequencing identified a new GES variant, GES-18, which differs from the carbapenem-hydrolyzing enzyme GES-5 by a single amino acid substitution (Val80Ile, in the numbering according to Ambler) and from GES-1 by two substitutions (Val80Ile and Gly170Ser). Detailed kinetic characterization showed that GES-18 and GES-5 hydrolyze imipenem and cefoxitin with similar kinetic parameters and that GES-18 was less susceptible than GES-1 to classical β-lactamase inhibitors such as clavulanate and tazobactam. The overall structure of GES-18 is similar to the solved structures of GES-1 and GES-2, the Val80Ile and Gly170Ser substitutions causing only subtle local rearrangements. Notably, the hydrolytic water molecule and the Glu166 residue were slightly displaced compared to their counterparts in GES-1. Our kinetic and crystallographic data for GES-18 highlight the pivotal role of the Gly170Ser substitution which distinguishes GES-5 and GES-18 from GES-1. Copyright © 2013, American Society for Microbiology. All Rights Reserved.
CITATION STYLE
Bebrone, C., Bogaerts, P., Delbrück, H., Bennink, S., Kupper, M. B., De Castro, R. R., … Hoffmann, K. M. (2013). GES-18, a new carbapenem-hydrolyzing GES-type β-lactamase from Pseudomonas aeruginosa that contains Ile80 and Ser170 residues. Antimicrobial Agents and Chemotherapy, 57(1), 396–401. https://doi.org/10.1128/AAC.01784-12
Mendeley helps you to discover research relevant for your work.